Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
暂无分享,去创建一个
P. Kantoff | A. Kibel | S. Signoretti | T. Choueiri | G. Bubley | G. Steele | J. Rosenberg | M. Hirsch | J. Bellmunt | L. Appleman | E. Stack | K. Krajewski | M. Taplin | A. Qu | C. Sweeney | R. Ross | S. Jacobus | C. Tretter | Meghara Walsh
[1] T. Powles,et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. , 2013, Clinical genitourinary cancer.
[2] J. Pignon,et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. , 2013, The New England journal of medicine.
[3] David J. Chen,et al. Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study. , 2012 .
[4] R. Millikan,et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Sonpavde,et al. Neoadjuvant Chemotherapy for Invasive Bladder Cancer , 2012, Current Urology Reports.
[6] R. Millikan,et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Kibel. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .
[8] H. Grossman,et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.
[9] E. Klein,et al. Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.
[10] J. Baselga,et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] R. Dienstmann,et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. , 2007, International braz j urol : official journal of the Brazilian Society of Urology.
[12] Elisabeth Brambilla,et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.
[13] J O Barentsz,et al. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. , 2006, European urology.
[14] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[15] L. Collette,et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Dearnaley,et al. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer , 2000, British Journal of Cancer.
[17] J. Witjes,et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.
[18] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Scher. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.
[20] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.
[21] C. Logothetis,et al. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. , 1986, The Journal of urology.
[22] Brown Bw,et al. Confidence limits for probability of response in multistage phase II clinical trials. , 1985 .
[23] E. Atkinson,et al. Confidence limits for probability of response in multistage phase II clinical trials. , 1985, Biometrics.